Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tofacitinib

tofacitinib

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tofacitinib

27 trials tracked of tofacitinib: 10 in phase 3 or 4 and 10 with published results. The most-cited published study has 731 citations.

27Trials tracked
10Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 2 Phase 3 8 Phase 2 7 Phase 1 3 Other / NA 7
  1. Phase 4 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed · 731 cited
  2. Phase 3 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed · 163 cited
  3. Phase 3 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis Completed · 120 cited
  4. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed · 120 cited
  5. Phase 3 Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis Completed · 41 cited
  6. Phase 3 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis Completed · 24 cited
Show 21 more trials
  1. Phase 3 Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis Completed · 24 cited
  2. Phase 4 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Completed · 15 cited
  3. Phase 3 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed · 7 cited
  4. Phase 3 Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS) Completed · 6 cited
  5. Phase 2 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Completed
  6. Phase 2 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate Completed
  7. Phase 2 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE Completed
  8. Phase 2 Tofacitinib for Immune Skin Conditions in Down Syndrome Completed
  9. Phase 2 A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate Completed
  10. Phase 2 Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed
  11. Phase 2 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Completed
  12. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  13. Phase 1 Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Completed
  14. Phase 1 Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis Completed
  15. N/A Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. Completed
  16. N/A Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed
  17. N/A A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis Completed
  18. N/A IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis Completed
  19. N/A Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN Completed
  20. N/A Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis Completed
  21. N/A Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients Completed

Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
Rheumatology Sys. Review
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Jul 18, 2026
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months
Psychiatry Cohort
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Frontiers Apr 16, 2026
Oral tofacitinib monotherapy with fire needling induced marked regression of cutaneous Rosai-Dorfman disease lesions in a single patient
Neurology Sys. Review
Oral tofacitinib monotherapy with fire needling induced marked regression of cutaneous Rosai-Dorfman disease lesions in a single patient A pill and a heated needle tamed a stubborn face disease
This case report and literature review describes a 55-year-old female with refractory cutaneous Rosai-Dorfman disease who failed prior thera…
A woman whose face was covered in stubborn red nodules finally saw improvement when doctors tried a surprising combination that crossed medi…
Frontiers Apr 13, 2026
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Dermatology Meta-analysis
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Apr 4, 2026
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance
Oncology Sys. Review
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance Review explores combining JAK inhibitors with immunotherapy for resistant cancers
A systematic review discusses the rationale for combining JAK inhibitors with PD-1 blockade immunotherapy based on emerging preclinical and …
Blocking inflammation around tumors with JAK inhibitors may help immune drugs work better for cancers that have stopped responding to standa…
Frontiers Apr 3, 2026
Tofacitinib used in single case of steroid-refractory multi-organ immune-related adverse events
Allergy & Immunology Cohort
Tofacitinib used in single case of steroid-refractory multi-organ immune-related adverse events Single case shows tofacitinib may help with severe immune side effects from cancer immunotherapy
A case report describes a 75-year-old female with colon cancer who developed steroid-refractory immune checkpoint inhibitor-associated myoca…
A single case shows tofacitinib helped a cancer patient recover from severe heart inflammation that steroids could not fix, though infection…
Frontiers Apr 3, 2026